Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 10/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 6/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 6/20 | 0.40 |
| ▸ | FAP | Q12884 | 3/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.40 |
| ▸ | PITRM1 | Q5JRX3 | 1/20 | 0.32 |
| ▸ | CTSD | P07339 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8514992 | 0.84 | DPP4 (0.48) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL9611390 | 0.84 | DPP4 (0.48) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL8510880 | 0.80 | XIAP (0.35) | LMNA | |
| SCHEMBL2707702 | 0.65 | LMNA (0.40) | DPP4LMNA | |
| SCHEMBL23394438 | 0.63 | DPP4 (0.51) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL26115928 | 0.63 | DPP4 (0.51) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL26115927 | 0.63 | DPP4 (0.51) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL8247400 | 0.63 | DPP4 (0.41) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL5941797 | 0.62 | DPP4 (0.49) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL15591635 | 0.62 | DPP4 (0.50) | DPP4DPP8DPP9FAPDPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8415486-B2 | IAP inhibitors | TETRALOGIC PHARMACEUTICALS CORP. (US) | 2013-04-09 | — | — | US | disclosed |
| US-20120135990-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUTICALS CORP. (US) | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135990-A1 | IAP INHIBITORS | XIAP, IAPP, BIRC5 | DPP4 34/4885LMNA 767/4885DPP8 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.